janus kinase (JAK) inhibitor in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
0.52 [0.30 ; 0.89 ] COV-BARRIER (critically ill), 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 3 0% 126 low not evaluable deathsdetailed results Cao, 2020 0.15 [0.01; 3.29]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
0.50 [0.29 ; 0.85 ] Cao, 2020, COV-BARRIER (critically ill), 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 4 0% 167 low not evaluable clinical deteriorationdetailed results Cao, 2020 0.11 [0.01; 2.21]
0.11 [0.01 ; 2.21 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvementdetailed results Cao, 2020 1.67 [0.84; 3.33]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
2.07 [1.21 ; 3.53 ] Cao, 2020, COV-BARRIER (critically ill), 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 4 0% 168 moderate not evaluable clinical improvement (14-day)detailed results Cao, 2020 2.00 [0.58; 6.94]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
1.98 [1.05 ; 3.71 ] Cao, 2020, COV-BARRIER (critically ill), 2022 2 0% 142 low not evaluable clinical improvement (21-day)detailed results Cao, 2020 1.50 [0.22; 10.08]
1.50 [0.22 ; 10.08 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (28-day)detailed results COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.92 [0.96 ; 3.82 ] COV-BARRIER (critically ill), 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 3 0% 126 low not evaluable clinical improvement (7-day)detailed results Cao, 2020 2.38 [0.38; 14.70]
2.38 [0.38 ; 14.70 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.67 [0.84; 3.33]
1.67 [0.84 ; 3.33 ] Cao, 2020 1 0% 42 NA not evaluable mechanical ventilationdetailed results Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
0.08 [0.01 ; 0.86 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable radiologic improvement (14-day)detailed results Cao, 2020 5.54 [1.01; 30.50]
5.54 [1.01 ; 30.50 ] Cao, 2020 1 0% 41 NA not evaluable recoverydetailed results COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
1.57 [0.77 ; 3.20 ] COV-BARRIER (critically ill), 2022 1 0% 101 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable serious adverse eventsdetailed results Cao, 2020 0.11 [0.01; 2.21]
0.11 [0.01 ; 2.21 ] Cao, 2020 1 0% 41 NA not evaluable adverse eventsdetailed results Cao, 2020 1.60 [0.38; 6.81]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
0.43 [0.04 ; 4.22 ] Cao, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 3 53% 66 moderate not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 01:42 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 1046,727,818,606,954,964,962,963,1045
- roots T: 290